Nymox Pharmaceutical Corporation

PNK:NYMXF

$0.0751 USD

$0.01 (7.29%)

Volume
600
Average Volume
16.76K
Market Capitalization
$14.03M
P/E Ratio
-0.94
Dividend Yield
0.00%
Price Target
$
Year High
$1.40
Year Low
$0.00
Payout Ratio
$0.00
Current Ratio
$0.16

Industry, Sector & symbol

Stock Exchange OTC Markets OTCPK
CEO Dr. Paul Averback DABP, M.D.
Industry Biotechnology
Sector Healthcare
Current Symbol NYMXF
CUSIP None
CIK None
Web https://nymox.com
Phone 800 936 9669
Currency USD
Employees None
Country BS

Liquidity

Debt-to-Equity Ratio -0.24
Payout Ratio 0.00
Current Ratio 0.16
Quick Ratio 0.16
Cash Ratio 0.02

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -0.03
Price / Cash Flow -4.55
Price / Book -2.21

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.0965
Trailing P/E Ratio -0.94
PEG Ratio 0.01
P/E Growth 0.01
Net Income $-8.84M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 281.33%
Return on Assets -1189.31%

Financials Score

AltmanZ Score -514.53
Piotroski Score 1.00
Working Capital -3.18M
Total Assets 627K
Ebit -8.79M
Market Cap 14.03M
Total Liabilities 3.8M

Poll Results

About Nymox Pharmaceutical Corporation (PNK:NYMXF) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas. ...

Nymox Announces Filing of Annual Report

2024-08-30 09:30:00

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.

Nymox Annual Report

2024-07-18 13:24:00

IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company's control in its completion. The Company believes that the audit will be completed soon, and it will issue its annual report as soon as possible thereafter.

Nymox Required to Resubmit Application to DKMA

2024-07-16 09:30:00

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required to extend the MAA application to DKMA by re-submission with a new fee required. As it currently stands the application “does not meet the conditions of the Medicines Act for issuing a marketing authorization.” Although a great number of questions were resolved by the Company, there remain further responses required that will require additional cycle time. The Company is busy analyzing the approaches that are possible. Nymox cannot guarantee that all questions can be resolved. The Company believes that it has the data required to formulate the required re-submission.

Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages

2024-03-27 09:36:00

IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by terminated ex-employees. The Order also awards to Nymox its costs incurred in defending the ill-conceived lawsuit, as well as damages Nymox has suffered as a result of the litigation.

Nymox December 27 Message to Shareholders

2023-12-27 10:13:00

IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.

Frequently Asked Questions

What is the current Nymox Pharmaceutical Corporation (NYMXF) stock price?

Nymox Pharmaceutical Corporation(PNK:NYMXF) stock price is $0.0751 in the last trading session. During the trading session, NYMXF stock reached the peak price of $4 while $1.0E was the lowest point it dropped to. The percentage change in NYMXF stock occurred in the recent session was 7.29% while the dollar amount for the price change in NYMXF stock was $0.01.

NYMXF's industry and sector of operation?

The PNK listed NYMXF is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of NYMXF?

Ms. Lin Dodd | QA and Compliance Manager
Dr. Paul Averback DABP, M.D. | Founder, Chairman, Chief Executive Officer & President
Mr. Patrick Doody | Vice President, General Counsel & Director
|
|

How many employees does NYMXF have?

Number of NYMXF employees currently stands at None. NYMXF operates from Bay & Deveaux Streets, Nassau, None None, BS.

Link for NYMXF official website?

Official Website of NYMXF is: https://nymox.com

How do I contact NYMXF?

NYMXF could be contacted at phone #800 936 9669 and can also be accessed through its website. NYMXF operates from Bay & Deveaux Streets, Nassau, None None, BS.

How many shares of NYMXF are traded daily?

The average number of NYMXF shares traded daily for last 3 months was 16.76K.

What is the market cap of NYMXF currently?

The market value of NYMXF currently stands at $14.03M with its latest stock price at $0.0751